The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Prognostic value of MRD and circulating plasma cells in myeloma
Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the importance of circulating plasma cells and measurable residual disease (MRD)-negativity as prognostic parameters in multiple myeloma. Long term follow-up studies have shown that the dynamics of circulating plasma cells have a predictive value in the risk of disease progression. Similarly, MRD has been shown in many studies to be predictive of outcome, irrespective of the technique used. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
